個人簡介：

Dr. An is the founder of Curegenix. He is an expert in WNT signaling research with more than 20 years of drug discovery experiences in pharmaceutical industry. Prior to founding Curegenix, he was a Principlal Scientist / Project Leader at Amgen and a program director at Tularik in the US. He obtained an MD degree from Peking University Medical School and a PhD degree in Molecular Biology / Biochemistry from the University of Missouri-Columbia. After postdoctoral training in immunology at the University of California, San Francisco (UCSF), Dr. An became an assistant professor in the Department of Medicine at UCSF.

公司簡介：

應用國際先進技術，研發全球首創First-in-class抗腫瘤、抗纖維化新藥 。廣州開發區科技領軍人才，廣州市創業領軍人才，國家十二五重大新藥創制專項，著名風險投資機構及跨國藥廠支持 。磷酸源生萘啶CGX1321完成中美雙報，開展國際多中心臨床試驗，在全球十多家頂級臨床中心完成臨床2a期試驗（Harvard, Johns Hopkins, Duke, 北京腫瘤醫院等) 。臨床試驗結果在美國臨床腫瘤學會 (ASCO) 2023年會上應邀做口頭報告 。自主研發項目聚焦WNT通路抑制劑，不涉獵其它靶點。將借助研發平臺和豐富經驗，為業內同仁提供臨床前研究服務、中美臨床試驗咨詢。